Wall Street brokerages expect Teladoc Health Inc (NYSE:TDOC) to announce earnings of ($0.33) per share for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Teladoc Health’s earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.40). Teladoc Health posted earnings per share of ($0.35) during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.7%. The firm is expected to issue its next earnings report on Wednesday, February 26th.

On average, analysts expect that Teladoc Health will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.47) to ($1.37). For the next financial year, analysts anticipate that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.41) to ($0.94). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Teladoc Health.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative net margin of 20.15% and a negative return on equity of 11.23%. The firm had revenue of $137.96 million during the quarter, compared to the consensus estimate of $136.46 million. During the same period in the previous year, the firm posted ($0.34) earnings per share. The business’s revenue was up 24.3% compared to the same quarter last year.

A number of analysts recently commented on the company. Zacks Investment Research lowered Teladoc Health from a “buy” rating to a “hold” rating and set a $89.00 target price for the company. in a research report on Wednesday, November 27th. Oppenheimer set a $83.00 price target on Teladoc Health and gave the stock a “buy” rating in a report on Friday, September 6th. SunTrust Banks reissued a “hold” rating and issued a $80.00 price objective on shares of Teladoc Health in a research note on Monday. ValuEngine raised Teladoc Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada initiated coverage on Teladoc Health in a report on Wednesday, November 27th. They set an “outperform” rating and a $100.00 price objective for the company. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $81.73.

In other Teladoc Health news, insider Adam C. Vandervoort sold 50,955 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total transaction of $3,821,625.00. Following the transaction, the insider now directly owns 9,769 shares in the company, valued at approximately $732,675. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Andrew Turitz sold 9,158 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $62.27, for a total value of $570,268.66. Following the transaction, the senior vice president now owns 6,827 shares in the company, valued at $425,117.29. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,907 shares of company stock worth $5,574,483. 3.14% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace North America L.P. purchased a new stake in shares of Teladoc Health in the first quarter valued at about $35,000. Commonwealth Equity Services LLC lifted its position in shares of Teladoc Health by 9.0% during the second quarter. Commonwealth Equity Services LLC now owns 31,143 shares of the health services provider’s stock valued at $2,068,000 after purchasing an additional 2,563 shares in the last quarter. Westside Investment Management Inc. bought a new position in shares of Teladoc Health during the second quarter valued at about $26,000. Artemis Investment Management LLP boosted its holdings in Teladoc Health by 4.9% during the second quarter. Artemis Investment Management LLP now owns 151,900 shares of the health services provider’s stock worth $9,800,000 after purchasing an additional 7,147 shares during the last quarter. Finally, Strs Ohio boosted its holdings in Teladoc Health by 12.9% during the second quarter. Strs Ohio now owns 284,204 shares of the health services provider’s stock worth $18,873,000 after purchasing an additional 32,423 shares during the last quarter.

TDOC stock opened at $78.88 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 6.55 and a quick ratio of 6.55. The company’s 50-day moving average is $76.85 and its 200-day moving average is $67.27. The stock has a market capitalization of $5.71 billion, a PE ratio of -54.78 and a beta of 1.40. Teladoc Health has a 1 year low of $42.08 and a 1 year high of $86.30.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Diversification

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.